Fatma Bahar SUNAY, Mehmet KÖSE, Nurhan SARIOĞLU, Fuat EREL, Oğuzhan KORKUT, Adnan Adil HİŞMİOĞULLARI, Arzu YAY, Betül YALÇIN

Antiinflammatory effects of adalimumab, tocilizumab, and steroid on lipopolysaccharide-induced lung injury

Background/aim: Acute lung injury (ALI) is a major cause of death in the intensive care unit. Lipopolysaccharide (LPS) induced lung injury is the most widely used experimental ALI model and provides opportunities for new targeting therapy. In this study, we investigated the effects of tocilizumab, adalimumab, and methylprednisolone in LPS-induced acute lung injury. Materials and methods: Lung injury was established by intratracheal instillation of LPS. The rats were randomly divided into six groups: LPS, control, and treatment groups (adalimumab, tocilizumab, methylprednisolone, adalimumab + tocilizumab). Bronchoalveolar lavage (BAL) and lung tissues were collected at 48 h and 96 h following LPS administration from each group. For histological analysis, hematoxylin–eosin (H&E) staining was performed. The sections were obtained for immunohistochemical analysis. IL-6 and TNF-alpha immunoreactivity were measured. Results: Intratracheal LPS application resulted in inflammatory cell infiltration of interstitial and alveolar spaces and thickening of the alveolar wall. All treatment groups showed significantly amelioration compared to LPS at 48 h. Interestingly, adalimumab and adalimumab + tocilizumab groups showed a significant amelioration of the lung histoarchitecture, compared to the prednisolone group at 96 h (p = 0.028, p = 0.025, respectively). Compared to the control group, LPS stimulation resulted in a significant increase in IL-6 and TNF-alpha immunoreactivity (p < 0.001). IL-6 and TNF-alpha expression were markedly reduced in all treatment groups at 48 h but the reduction was greater in the adalimumab and tocilizumab group than in the steroid. Administration with adalimumab and/or tocilizumab effectively decreased expression of TNF-alpha (p = 0.001) and IL-6 (p < 0.001) at 96 h, but prednisolone did not exert an effective decrease (p > 0.05). Conclusion: Adalimumab and/or tocilizumab significantly reduce the release of proinflammatory cytokines and improve the tissue inflammation in the experimental model of ALI. Our results suggest that adalimumab and/or tocilizumab have a more potent antiinflammatory effect on lung injury than the steroid.Key words: Adalimumab, tocilizumab, steroid, acute lung injury

PDF

___

1. Wheeler AP, Bernard GR. Acute lung injury and the acute respiratory distress syndrome: a clinical review. Lancet 2007; 369: 1553–1564. doi: 10.1016/S0140-6736(07)60604-7
2. Zhang Y, Liang D, Dong L, Ge X, Xu F et al. Anti-inflammatory effects of novel curcumin analogs in experimental acute lung injury. Respiratory Research 2015; 16(1): 43. doi: 10.1186/ s12931-015-0199-1
3. Du ZA, Sun MN, Hu ZS. Saikosaponin an Ameliorates LPSInduced Acute Lung Injury in Mice. Inflammation 2018; 41(1): 193-198. doi: 10.1007/s10753-017-0677-3
4. Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome. Journal of Pathology 2004; 202(2): 145-156. doi: 10.1002/ path.1491
5. Lei J, Wei Y, Song P, Li Y, Zhang T et al. Cordycepin inhibits LPS-induced acute lung injury by inhibiting inflammation and oxidative stress. European Journal of Pharmacology 2018; 818: 110-114. doi: 10.1016/j.ejphar.2017.10.029
6. Akdis M, Burgler S, Crameri R, Eiwegger T, Fujita H et al. Interleukins, from 1 to 37, and interferon-γ: receptors, functions, and roles in diseases. Journal of Allergy and Clinical Immunology 2011; 127(3): 701-721.e1-70. doi: 10.1016/j. jaci.2010.11.050
7. Bouros D, Alexandrakis MG, Antoniou KM, Agouridakis P, Pneumatikos I et al. The clinical significance of serum and bronchoalveolar lavage inflammatory cytokines in patients at risk for Acute Respiratory Distress Syndrome. BMC Pulmonary Medicine 2004; 4: 6. doi: 10.1186/1471-2466-4-6
8. Butt Y, Kurdowska A, Allen TC. Acute Lung Injury: A Clinical and Molecular Review. Archives of Pathology & Laboratory Medicine 2016; 140(4): 345-350. doi: 10.5858/arpa.2015-0519- RA
9. Xiao R, Chen R. Neutrophil gelatinase-associated lipocalin as a potential novel biomarker for ventilator-associated lung injury. Molecular Medicine Reports 2017; 15(6): 3535-3540. doi: 10.3892/ mmr.2017.6442
10. Xu SY, Carlson M, Engström A, Garcia R, Peterson CG et al. Purification and characterization of a human neutrophil lipocalin (HNL) from the secondary granules of human neutrophils. Scandinavian Journal of Clinical and Laboratory Investigation 1994; 54(5): 365-376. doi: 10.3109/00365519409088436
11. Gwira JA, Wei F, Ishibe S, Ueland JM, Barasch J et al. Expression of neutrophil gelatinase-associated lipocalin regulates epithelial morphogenesis in vitro. Journal of Biological Chemistry 2005; 280(9): 7875-7882. doi: 10.1074/jbc.M413192200
12. Dong Z, Yuan Y. Accelerated inflammation and oxidative stress induced by LPS in acute lung injury: iotanhibition by ST1926. International Journal of Molecular Medicine 2018; 41(6): 3405-3421. doi: 10.3892/ ijmm.2018.3574.
13. Qin M, Qiu Z. Changes in TNF-α, IL-6, IL-10 and VEGF in rats with ARDS and the effects of dexamethasone. Experimental and Therapeutic Medicine 2019; 17(1): 383-387. doi: 10.3892/ etm.2018.6926
14. Fein AM, Calalang-Colucci MG. Acute lung injury and acute respiratory distress syndrome in sepsis and septic shock. Critical Care Clinics 2000; 16(2): 289-317. doi: 10.1016/s0749- 0704(05)70111-1
15. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ et al. IL22 mediates mucosal host defense against Gram-negative bacterial pneumonia. Nature Medicine 2008; 14(3): 275-281. doi: 10.1038/ nm1710
16. Rice P, Martin E, He JR, Frank M, DeTolla L et al. Febrilerange hyperthermia augments neutrophil accumulation and enhances lung injury in experimental gram-negative bacterial pneumonia. Journal of Immunology 2005; 174(6): 3676-3685. doi: 10.4049/jimmunol. 174.6.3676
17. Matute-Bello G, Frevert CW, Martin TR. Animal models of acute lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology 2008; 295(3): L379-399. doi: 10.1152/ajplung.00010.2008
18. Chen H, Bai C, Wang X. The value of the lipopolysaccharideinduced acute lung injury model in respiratory medicine. Expert Review of Respiratory Medicine 2010; 4(6): 773-783. doi: 10.1586/ers.10.71
19. Lewis SR, Pritchard MW, Thomas CM, Smith AF. Pharmacological agents for adults with acute respiratory distress syndrome. Cochrane Database of Systematic Reviews 2019; 7(7): CD004477. doi: 10.1002/14651858.CD004477.pub3
20. Matthay MA, McAuley DF, Ware LB. Clinical trials in acute respiratory distress syndrome: challenges and opportunities. The Lancet Respiratory Medicine 2017; 5(6): 524-534. doi: 10.1016/S2213-2600(17)30188-1
21. Mokra D, Mikolka P, Kosutova P, Mokry J. Corticosteroids in Acute Lung Injury: The Dilemma Continues. International Journal of Molecular Sciences 2019; 20(19): 4765. doi: 10.3390/ ijms20194765
22. Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Annals of the Rheumatic Diseases 2013; 72(4): 517-524. doi: 10.1136/annrheumdis-2011-201244
23. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I et al. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clinical Rheumatology 2020; 39(7): 2085-2094. doi: 10.1007/s10067- 020-05190-5
24. Khiali S, Khani E, Entezari-Maleki T. A Comprehensive Review of Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome. The Journal of Clinical Pharmacology 2020; 60(9): 1131-1146. doi: 10.1002/jcph.1693
25. Chen KL, Lv ZY, Yang HW, Liu Y, Long FW et al. Effects of Tocilizumab on Experimental Severe Acute Pancreatitis and Associated Acute Lung Injury. Critical Care Medicine 2016; 44(8): e664-77. doi: 10.1097/CCM.0000000000001639
26. Ibrahim YF, Moussa RA, Bayoumi AMA, Ahmed AF. Tocilizumab attenuates acute lung and kidney injuries and improves survival in a rat model of sepsis via down-regulation of NF-κB/JNK: a possible role of P-glycoprotein. Inflammopharmacology 2020; 28(1): 215-230. doi: 10.1007/s10787-019-00628-y
27. Kurt A, Tumkaya L, Kalkan Y, Turut H, Cure MC et al. Is adalimumab protective in ischemia-reperfusion injury in lung? Iranian Journal of Basic Medical Sciences 2015; 18(11): 1093- 1099
28. Correger E, Marcos J, Laguens G, Stringa P, CardinalFernández P et al. Pretreatment with adalimumab reduces ventilator-induced lung injury in an experimental model. Revista Brasileira de Terapia Intensiva 2020; 32(1): 58-65. doi: 10.5935/0103-507x.20200010
29. Tu GW, Shi Y, Zheng YJ, Ju MJ, He HY et al. Glucocorticoid attenuates acute lung injury through induction of type 2 macrophage. Journal of Translational Medicine 2017; 15(1): 181. doi: 10.1186/s12967-017-1284-7
30. Vega AM, Chupin C, Pascariu M, Privé A, Dagenais A et al. Dexamethasone fails to improve bleomycin-induced acute lung injury in mice. Physiological Reports 2019; 7(21): e14253. doi: 10.14814/phy2.14253
31. Betsuyaku T, Shipley JM, Liu Z, Senior RM. Neutrophil emigration in the lungs, peritoneum, and skin does not require gelatinase B. American Journal of Respiratory Cell and Molecular Biology 1999; 20(6): 1303-1309. doi: 10.1165/ ajrcmb.20.6.3558
32. Haegens A, Heeringa P, van Suylen RJ, Steele C, Aratani Y et al. Myeloperoxidase deficiency attenuates lipopolysaccharideinduced acute lung inflammation and subsequent cytokine and chemokine production. Journal of Immunology 2009; 182(12): 7990-7996. doi: 10.4049/ jimmunol.0800377
33. Herfs M, Hubert P, Poirrier AL, Vandevenne P, Renoux V et al. Proinflammatory cytokines induce bronchial hyperplasia and squamous metaplasia in smokers: implications for chronic obstructive pulmonary disease therapy. American Journal of Respiratory Cell and Molecular Biology 2012; 47(1): 67-79. doi: 10.1165/rcmb.2011-0353OC
34. Xie K, Yu Y, Pei Y, Hou L, Chen S et al. Protective effects of hydrogen gas on murine polymicrobial sepsis via reducing oxidative stress and HMGB1 release. Shock 2010; 34(1): 90-97. doi: 10.1097/SHK.0b013e3181cdc4ae
35. Abraham E, Jesmok G, Tuder R, Allbee J, Chang YH. Contribution of tumor necrosis factor-alpha to pulmonary cytokine expression and lung injury after hemorrhage and resuscitation. Critical Care Medicine 1995; 23(8): 1319-1326. doi: 10.1097/00003246-199508000-00004
36. Schindler R, Mancilla J, Endres S, Ghorbani R, Clark SC et al. Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75(1): 40–47
37. Lee J, Lee S, Zhang H, Hill MA, Zhang C et al. Interaction of IL-6 and TNF-alpha contributes to endothelial dysfunction in type 2 diabetic mouse hearts. PLoS One 2017; 12(11): e0187189. doi: 10.1371/journal.pone.0187189
38. Antwi-Amoabeng D, Kanji Z, Ford B, Beutler BD, Riddle MS et al. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review. Journal of Medical Virology 2020; 92(11): 2516-2522. doi: 10.1002/jmv.26038
39. ElSeirafi MM, Hasan HM, Sridharan K, Zamoori A, Alkhawaja S et al. Efficacy and safety of tocilizumab in critically ill adults with COVID-19 infection in Bahrain: A report of 5 cases. Respiratory Medicine Case Reports 2020; 30: 101139. doi: 10.1016/j.rmcr.2020.101139
40. Rilinger J, Kern WV, Duerschmied D, Supady A, Bode C et al. A prospective, randomised, double blind placebo-controlled trial to evaluate the efficacy and safety of tocilizumab in patients with severe COVID-19 pneumonia (TOC-COVID): A structured summary of a study protocol for a randomised controlled trial. Trials 2020; 21(1): 470. doi: 10.1186/s13063- 020-04447-3
41. Utz JP, Jinnur PK, Yi ES, Ryu JH, Midthun DE et al. Acute Bilateral Pulmonary Opacities Associated With Use of Tocilizumab. Journal of Clinical Rheumatology 2015; 21(7): 382-385. doi:10.1097/ RHU.0000000000000304
42. Kohli R, Namek K. Adalimumab (Humira) induced acute lung injury. American Journal of Case Reports 2013; 14: 173-175. doi: 10.12659/AJCR.889200